Galectin Therapeutics Executive Chairman, James Czirr to Appear on “The RedChip Money Report” on FOX Business News

  Galectin Therapeutics Executive Chairman, James Czirr to Appear on “The
  RedChip Money Report” on FOX Business News

Business Wire

NORCROSS, Ga. -- February 7, 2013

James Czirr, Executive Chairman of Galectin Therapeutics (NASDAQ: GALT), the
leading developer of therapeutics that target galectin proteins to treat
fibrosis and cancer, will be a guest on “The RedChip Money Report”™ television
program featuring emerging growth companies on FOX Business News, Saturday,
February 9, 2013 at 2:30 p.m. Eastern.

“The RedChip Money Report”™ delivers insightful commentary on small-cap
investing, interviews with Wall Street analysts, financial book reviews, as
well as featured interviews with executives of public companies. The show is
hosted by Dave Gentry, a leading authority on small-cap stocks and president
of RedChip, an international small-cap research firm and an Inc. 5000 company.
The program airs in a paid programming block with the network
http://www.redchip.com/media/mediamain.asp?page=redchiptv&pl=PLgBW00-WEinAN4lnGanOG7hEJALqRJzAi&from=services.

WHO: James Czirr, Executive Chairman, Galectin Therapeutics

WHAT: FOX Business News “The RedChip Money Report”

WHEN: Saturday, February 9, 2013, 2:30 PM, Eastern

About Galectin Therapeutics

Galectin Therapeutics (NASDAQ: GALT) is developing promising
carbohydrate-based therapies for the treatment of fibrotic liver disease and
cancer based on the Company's unique understanding of galectin proteins, key
mediators of biologic function. We are leveraging extensive scientific and
development expertise as well as established relationships with external
sources to achieve cost effective and efficient development. We are pursuing a
clear development pathway to clinical enhancement and commercialization for
our lead compounds in liver fibrosis and cancer. Additional information is
available at www.galectintherapeutics.com.

Contact:

Galectin Therapeutics Inc.
Peter G. Traber, MD, 678-620-3186
President, CEO & CMO
ir@galectintherapeutics.com